Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesLaboratory/PathologyBCBS Rhode Island Vitamin D Coverage Update | Open…
    Ask Trek AI about this page
    DraftBlue Cross Blue Shield - Rhode IslandPolicy N/A

    Vitamin-D Testing

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts

    Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and medical necessity for 25-hydroxy and 1,25-dihydroxy vitamin-D laboratory testing for Medicare Advantage and Commercial members, including covered indications, repeat-testing requirements, and exclusions.

    Policy Summary
    PayerBlue Cross Blue Shield - Rhode Island
    PolicyVitamin-D Testing
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateMar 1, 2027
    Last ReviewNov 4, 2026
    Next Review DateN/A
    Key ActionSubmit each laboratory service with a covered diagnosis from the applicable diagnosis-code attachment.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3Vitamin-D testing codes identified
    25-OHPreferred initial assay
    20–50Stable range for repeat-testing review
    <20 or >60Follow-up range
    Excluded

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Routine screening

    Vitamin-D Testing Coverage Criteria

    25-hydroxyvitamin D covered indications

    Covered when all of the following are met:

    Covered 25-hydroxyvitamin D testing

    • Qualifying indication

      • One of the following indications

        • Chronic kidney disease stage III or greater; chronic use of anticonvulsant medications or corticosteroids; cirrhosis or chronic liver disease; malabsorption states; hypocalcemia; hypercalcemia; hypercalciuria; hypervitaminosis D; parathyroid disorders; obstructive jaundice; osteomalacia; osteopenia; osteosclerosis or petrosis; rickets; or vitamin-D deficiency on replacement therapy related to a listed condition, to monitor treatment efficacy.
        • Osteoporosis with at least one qualifying criterion

          • At least one osteoporosis criterion

            • DEXA T-score <−2.5.T-score <−2.5
            • History of fragility fractures.
            • FRAX 10-year probability of hip fracture >3% or 10-year probability of another major osteoporotic fracture >20%.>3% hip-fracture probability or >20% major osteoporotic-fracture probability
            • FRAX probability for any fracture >3% with a T-score <−1.5.>3% any-fracture probability with T-score <−1.5
            • Initiation of bisphosphonate therapy.

              Vitamin-D and serum calcium levels should be determined and managed as necessary before bisphosphonate therapy is initiated.

    1,25-dihydroxyvitamin D covered indications

    Covered when all of the following are met:

    Covered 1,25-dihydroxyvitamin D testing

    • Qualifying indication

      • Unexplained hypercalcemia with suspected granulomatous disease or lymphoma.
      • Unexplained hypercalciuria with suspected granulomatous disease or lymphoma.
      • Suspected genetic childhood rickets.
      • Suspected tumor-induced osteomalacia.
      • Nephrolithiasis or hypercalciuria.

    Repeat testing and treatment monitoring

    Follow-up testing is covered or reimbursable only when medically necessary:

    Repeat testing or treatment monitoring

    • Applicable follow-up circumstance

      • The vitamin-D level is <20 ng/mL or >60 ng/mL; subsequent level(s) may be reimbursed until the level is within the normal range.<20 ng/mL or >60 ng/mL
      • The vitamin-D level is between 20 and 50 ng/mL and the patient is clinically stable; repeat testing is often unnecessary, and if performed, the medical necessity must be clearly documented.20–50 ng/mL

        Both assays need not be repeated for each condition.

    Routine or other screening vitamin-D testing is not permitted under this policy. Testing must be supported by a covered clinical indication.

    Vitamin-D testing for indications outside those identified as covered is not covered for Medicare Advantage and is not medically necessary for Commercial Products.

    Services determined to be not medically necessary, including medically necessary services that are non-covered benefits in some circumstances, may not be payable under the member’s applicable benefits. The member may not be charged unless the member was informed in advance and agreed in writing to continue treatment at the member’s own expense.

    For Commercial Products, vitamin-D testing for indications other than the covered diagnosis-based indications is not medically necessary, because the policy finds no indication that the technology improves the net health outcome.

    Services determined to be not medically necessary are subject to the policy’s member billing and nonpayment provisions. A provider may charge the member only after informing the member in advance and obtaining written agreement to continue treatment at the member’s own expense.

    Covered Codes and Coding Rules

    Medicare Advantage Plans and Commercial Products—25-hydroxy vitamin-D testingCPTCovered
    82306Vitamin D; 25 hydroxy, includes fraction(s), if performed
    0038UVitamin D, 25 hydroxy D2 and D3, by LC-MS/MS, serum microsample, quantitative
    1,25-dihydroxy vitamin-D testingCPTCovered
    82652Vitamin D; 1, 25 dihydroxy, includes fraction(s), if performed
    Stable-patient repeat testing
    Stable range20–50 ng/mL
    Repeat testingOften unnecessary when the patient is clinically stable
    DocumentationIf repeat testing is performed, medical necessity must be clearly documented
    Low or high vitamin-D level follow-up
    Low levelBelow 20 ng/mL
    High levelAbove 60 ng/mL
    Reimbursement

    Provider Documentation and Billing Actions

    Documentation Required

    Document Medical Necessity for Repeat Testing

    If a patient is clinically stable and the vitamin D level is between 20 and 50 ng/mL, repeat testing is often unnecessary. If repeat testing is performed, the medical record must clearly document why the test is medically necessary.

    Billing Rule

    Submit a Covered Diagnosis

    File vitamin D laboratory services with an applicable covered diagnosis from the policy’s diagnosis list. Covered services include the specified vitamin D assays when submitted with a covered diagnosis.

    • CPT 82306 — Vitamin D; 25 hydroxy
    • CPT 82652 — Vitamin D; 1,25 dihydroxy
    • CPT 0038U — Vitamin D, 25 hydroxy D2 and D3, by LC-MS/MS

    Clinical Background

    Hypovitaminosis D may result from inadequate dietary intake or sunlight exposure, malabsorption, liver or kidney disease, or genetic disease, and may lead to inadequate bone mineralization. 25-hydroxyvitamin D reflects total body vitamin-D stores and is generally preferred for initial evaluation, while 1,25-dihydroxyvitamin D testing is generally reserved for conditions affecting vitamin-D metabolism, particularly kidney disease and selected liver, parathyroid, or genetic disorders.

    Vitamin-D Assay Definitions

    25-hydroxyvitamin D
    MeasureCirculating 25-hydroxyvitamin D
    Relationship to storesMore reflective of total body vitamin-D stores than 1,25-dihydroxyvitamin D
    Preferred rolePreferred initial assay in the evaluation of most patients with hypovitaminosis D
    1,25-dihydroxyvitamin D
    MetaboliteActive vitamin-D metabolite
    FormationProduced when 25-hydroxyvitamin D undergoes additional hydroxylation in the kidney
    UseReserved for selected conditions affecting vitamin-D metabolism, including kidney, liver, parathyroid, or genetic diseases

    Diagnosis-Specific Covered Indications

    25-hydroxyvitamin D covered indications

    25-hydroxyvitamin D testing is covered for a qualifying indication when all applicable requirements are met:

    Qualifying indication

    • Chronic kidney disease stage III or greater.
    • Chronic use of anticonvulsant medications or corticosteroids.
    • Cirrhosis or chronic liver disease.
    • Malabsorption states.
    • Hypocalcemia, hypercalcemia, hypercalciuria, or hypervitaminosis D.

    Repeat Testing Frequency Limits

    Vitamin-D testing
    Stable patient range20–50 ng/mL
    Repeat testingOften unnecessary when the patient is clinically stable
    Medical necessityIf performed, documentation must clearly indicate the necessity of the test
    Vitamin-D testing
    Below normal rangeBelow 20 ng/mL
    Above normal rangeAbove 60 ng/mL
    Subsequent testingSubsequent level(s) may be reimbursed until the level is within the normal range

    Authorization and Appeals

    Prior Authorization

    Ordering physician must handle authorization and appeals

    Only the ordering physician may be involved in authorization, appeal, or other administrative processes related to prior authorization or medical necessity. Laboratories and laboratory-affiliated representatives may not obtain authorization on the physician’s behalf or facilitate any portion of the authorization or appeal process.

    Excluded Testing

    Routine or other screening vitamin-D testing is not covered.

    Vitamin-D testing for indications other than those identified as covered is not covered. For Medicare Advantage, these indications are not covered; for Commercial Products, they are not medically necessary.

    Policy Summary
    PayerBlue Cross Blue Shield - Rhode Island
    PolicyVitamin-D Testing
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateMar 1, 2027
    Last ReviewNov 4, 2026
    Next Review DateN/A
    Key ActionSubmit each laboratory service with a covered diagnosis from the applicable diagnosis-code attachment.
    SourceLink
    On This Page
    Vitamin-D Testing Coverage CriteriaCovered Codes and Coding RulesProvider Documentation and Billing ActionsClinical BackgroundVitamin-D Assay DefinitionsDiagnosis-Specific Covered IndicationsRepeat Testing Frequency LimitsAuthorization and AppealsExcluded Testing
    Subsequent level(s) may be reimbursed until the level is within the normal range
    Osteoporosis FRAX criterion
    Hip fractureMore than 3% 10-year probability of hip fracture
    Major osteoporotic fracture20% 10-year probability of another major osteoporotic fracture
    ApplicationEither probability threshold satisfies the listed osteoporosis criterion
    Osteoporosis combined FRAX and DEXA criterion
    FRAX probabilityMore than 3% probability of any fracture
    DEXA findingT-score below −1.5
    Combined criterionBoth the FRAX probability and T-score threshold must be met
    Osteoporosis DEXA criterion
    DEXA measureT-score on DEXA scan
    ThresholdBelow −2.5
    Qualifying conditionOsteoporosis meeting this threshold is a listed indication for 25-hydroxyvitamin D testing

    Unsupported block type: documentation

    Prior Authorization

    Laboratory May Not Obtain Authorization

    Laboratories may not obtain clinical authorization or participate in authorization, appeal, or related administrative processes on behalf of the ordering physician. Only the ordering physician may participate, including in preparing documentation of clinical appropriateness.

    • A laboratory or laboratory-affiliated representative may not obtain authorization or facilitate an appeal.
    • An unauthorized service is denied as the participating laboratory’s financial liability and may not be billed to the member.
    • Violation may result in severe action, up to and including termination from the BCBSRI provider network.
    Denial Risk

    Avoid Unsupported Indications and Screening

    Services for unsupported indications are not covered for Medicare Advantage and are not medically necessary for Commercial Products. Vitamin D testing may not be used for routine or other screening.

    • Both vitamin D assays need not be performed for each condition.
    • Further testing after deficiency is demonstrated may be medically necessary only to confirm adequate replacement.
    • When a level is below 20 ng/mL or above 60 ng/mL, subsequent testing may be reimbursed until the level is within the normal range.
    Billing Rule

    Noncovered or Not Medically Necessary Services

    If a service is determined to be not medically necessary or, where applicable, a medically necessary service is a non-covered benefit, the provider may not charge the member unless the member was informed in advance and agreed in writing to receive the service at the member’s own expense. Without that advance written agreement, the member is not responsible for payment.

    • Member billing is permitted only after advance notice and written agreement.
    • Benefits and eligibility are governed by the member’s applicable subscriber, certificate, or employer agreement.
    Parathyroid disorder.
  1. Obstructive jaundice.
  2. Osteomalacia, osteopenia, osteosclerosis or petrosis, or rickets.
  3. Osteoporosis with at least one qualifying criterion

    • At least one osteoporosis criterion

      • DEXA T-score <−2.5.T-score <−2.5
      • History of fragility fractures.
      • FRAX 10-year probability of hip fracture >3% or 10-year probability of another major osteoporotic fracture >20%.>3% hip-fracture probability or >20% major osteoporotic-fracture probability
      • FRAX probability for any fracture >3% with a T-score <−1.5.>3% any-fracture probability with T-score <−1.5
      • Initiation of bisphosphonate therapy.

        Vitamin-D and serum calcium levels should be determined and managed as necessary before bisphosphonate therapy is initiated.

  4. Vitamin-D deficiency on replacement therapy related to a listed condition, to monitor treatment efficacy.
  5. 1,25-dihydroxyvitamin D covered indications

    1,25-dihydroxyvitamin D testing is covered for a qualifying indication when medically necessary:

    Qualifying indication

    • Unexplained hypercalcemia with suspected granulomatous disease or lymphoma.
    • Unexplained hypercalciuria with suspected granulomatous disease or lymphoma.
    • Suspected genetic childhood rickets.
    • Suspected tumor-induced osteomalacia.
    • Nephrolithiasis or hypercalciuria.